Article | March 8, 2021

12 Ways To Avoid Delays In Hemato-Oncology Trials

Source: Cmed Clinical Research Services
Red Blood Cells

The COVID-19 pandemic has exacerbated the usual factors that can impact the start of clinical trials, including the need for the right study design, patient recruitment, appropriate inclusion/exclusion criteria, commercial/risk concerns and compliance with international regulatory constraints. While the world has waited anxiously for the industry to demonstrate an effective therapy for COVID-19, investors have shown caution in backing trials for other therapies given the delays and additional costs now associated with trials.

Our clinical operations team have pulled together useful ideas to reduce startup delays that they have gleaned from over 57 hematology-oncology trials with pediatric, adult and elderly populations.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader

Cmed Clinical Research Services